|
|
|
|
 |
Volume 11, Issue 4 (winter 2015) |
 |
|
|
|
|
Association between G-436 A (rs2333227) polymorphism at myeloperoxidase gene promoter andcoronary artery disease risk in Iranian patients
|
P. Mohammadi   , S. Soleimani , Z. Sharifi , A. Nouruzi , M. Najafi |
|
|
| Keywords: Key words: Coronary Artery Disease, Reactive Oxygen Species, Coronary Stenosis, Risk Factors |
|
|
Full-Text [PDF 285 kb]
(1603 Downloads)
| Abstract (HTML) (7091 Views)
|
Type of Study: Research |
Subject:
Biochemistry
Published: 2014/12/31
|
|
|
|
|
|
|
Full-Text: (1295 Views) |
References :
- Kothari N, Keshari RS, Bogra J, Kohli M, Abbas H, Malik A, et al. Increased myeloperoxidase enzyme activity in plasma is an indicator of inflammation and onset of sepsis. J Crit Care 2011; 26(4): 435. e1-7.
- Mäkelä R, Loimaala A, Nenonen A, Mercuri M, Vuori I, Huhtala H, et al. The association of myeloperoxidase promoter polymorphism with carotid atherosclerosis is abolished in patients with type 2 diabetes. Clin Biochem 2008; 41(7-8): 532-7.
- Zhang R, Brennan ML, Fu X, Aviles RJ, Pearce GL,
Penn MS, et al. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 2001; 286(17): 2136-42.
- He C, Tamimi RM, Hankinson SE, Hunter DJ, Han J. A prospective study of genetic polymorphism in MPO, antioxidant status, and breast cancer risk. Breast Cancer Res Treat 2009; 113(3): 585-94.
- Wainstein RV, Wainstein MV, Ribeiro JP, Dornelles LV, Tozzati P, Ashton-Prolla P, et al. Association between myeloperoxidase polymorphisms and its plasma levels with severity of coronary artery disease. Clin Biochem 2010; 43(1-2): 57-62.
- Banerjee M, Banerjee N, Ghosh P, Das JK, Basu S, Sarkar AK, et al. Evaluation of the serum catalase and myeloperoxidase activities in chronic arsenic-exposed individuals and concomitant cytogenetic damage. Toxicol Appl Pharmacol 2010; 249(1): 47-54.
- Kizaki M, Miller CW, Selsted ME, Koeffler HP. Myeloperoxidase (MPO) gene mutation in hereditary MPO deficiency. Blood 1994; 83(7): 1935-40.
- Nicholls SJ, Hazen SL. Myeloperoxidase and cardiovascular disease. Arterioscler Thromb Vasc Biol 2005; 25(6): 1102-11.
- Chevrier I, Tregouet DA, Massonnet-Castel S, Beaune P, Loriot MA. Myeloperoxidase genetic polymorphisms modulate human neutrophil enzyme activity: genetic determinants for atherosclerosis? Atherosclerosis 2006; 188(1): 150-4.
- Videm V, Olsen GD. No relationship between neutrophil granulocyte activation and the
myeloperoxidase gene - 129 G>A and - 463 G>A promoter polymorphisms: implications for investigations of cardiovascular disease. Coron Artery Dis 2009; 20(7): 446-52.
- Zotova E, Lyrenas L, de Faire U, Morgenstern R, Gigante B, Bennet AM. The myeloperoxidase gene and its influence on myocardial infarction in a Swedish population: protective role of the -129A allele in women. Coron Artery Dis 2009; 20(5): 322-6.
- Ergen A, Isbir S, Timirci O, Tekeli A, Isbir T. Effects of myeloperoxidase -463 G/A gene polymorphism and plasma levels on coronary artery disease. Mol Biol Rep 2011; 38(2): 887-91.
- Nikpoor B, Turecki G, Fournier C, Theroux P, Rouleau GA. A functional myeloperoxidase polymorphic variant is associated with coronary artery disease in French-Canadians. Am Heart J 2001; 142(2): 336-9.
- Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16(3): 1215.
|
Sci J Iran Blood Transfus Organ 2015; 11(4): 286-294
|
Association between G-436 A (rs2333227) polymorphism at myeloperoxidase gene promoter and coronary artery
disease risk in Iranian patients
Mohammadi P.1, Soleimani S.2, Sharifi Z.2, Nouruzi A.3, Najafi M.4
- Tehran University of Medical Sciences, Tehran, Iran
- Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran
- Tehran University of Medical Sciences, Tehran, Iran
- Immunology Research Center, Iran University of Medical Sciences, Tehran, Iran
Background and Objectives
Polymorphonuclear cell-derived myeloperoxidase (MPO) is a known agent in the progression of inflammatory disorders via the production of reactive oxygen species. In this study, we investigated the association between rs2333227 polymorphism ( G-436 A) within the MPO gene promoter and coronary artery stenosis.
Materials and Methods
A total of 160 Iranian subjects (patients = 86 and controls = 74) were introduced on the basis of the study criteria. DNA was extracted from white blood cells and the genotype distribution was evaluated by PCR-RFLP technique
Results
The AA, AG and GG genotype frequencies in study population were calculated to be 6.90%, 39.4% and 53.7%, respectively (p > 0.21). There was no significant difference between the genotype distribution and the extent of coronary stenosis in patients with 1VD, 2VD and 3VD (p = 0.71). The A allele frequencies were 25.6% and 27.4% in patients and controls, respectively.
Conclusions
In general, our results indicate that the Iranian population genotype and allele distribution do not play a role in the development and severity of coronary artery disease.
Key words: Coronary Artery Disease, Reactive Oxygen Species, Coronary Stenosis, Risk Factors
Received: 22 Jan 2014
Accepted:14 Jun 2014
Correspondence: Najafi M., PhD of Biochemistry. Associate Professor of Immunology Research Center, Iran University of Medical Sciences.
P.O.Box: 14155-5983, Tehran, Iran. Tel: (+9821) 86703107; Fax: (+9821) 86703107
E-mail:
nbsmmsbn@tums.ac.ir
|
|
| Send email to the article author |
|
|
|
| Add your comments about this article |
|
|
|
|
mohammadi P, soleimani S, Sharifi Z, Nouruzi A, Najafi M. Association between G-436 A (rs2333227) polymorphism at myeloperoxidase gene promoter andcoronary artery disease risk in Iranian patients. Sci J Iran Blood Transfus Organ 2015; 11 (4) :286-294 URL: http://bloodjournal.ir/article-1-838-en.html
|
|
|
|
|
|
|
.jpg)
.png)
